Aldapt, M., Wang, Y.-H., Shah, K. J., El Kettani, M., Foran, J., Kharfan-Dabaja, M., Murthy, H., Al-Kali, A., Shah, M. V., Alkhateeb, H., Saliba, A. N., Hogan, W., Yi, C. A., Sproat, L., Punwani, N., Khera, N., Palmer, J., Litzow, M., Tefferi, A., Gangat, N., Patnaik, M. M. and Badar, T. (2020) “Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in <i>TP53</i&gt;-mutated myelodysplastic syndromes”, Haematologica. Pavia, Italy. doi: 10.3324/haematol.2025.289268.